Pembrolizumab in High-risk Thyroid Cancer
Pembrolizumab in High-risk Thyroid Cancer
Recruiting · NCT05852223 · Registry updated 2026-04-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab in High-risk Thyroid Cancer | differentiated thyroid carcinoma | Recruiting | Phase 2 | 2026-04-20 | NCT05852223 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Istituti Clinici Scientifici Maugeri SpA | 75 |
| Merck Sharp & Dohme LLC | 650 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Istituti Clinici Scientifici Maugeri | Pavia | Italy | 2 |